Loading…
Collegium Pharmaceutical, Inc. is projected to rise to $38.30 by 2027, a +9% move from its current price of $35.23. COLL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $34.58 | $35.25 | $35.94 | +0.06% |
| Jul 15 | $34.32 | $35.27 | $36.25 | +0.11% |
| Jul 16 | $34.13 | $35.29 | $36.49 | +0.17% |
| Jul 17 | $33.97 | $35.31 | $36.70 | +0.22% |
| Jul 18 | $33.84 | $35.33 | $36.89 | +0.28% |
| Jul 19 | $33.72 | $35.35 | $37.06 | +0.34% |
| Jul 20 | $33.61 | $35.37 | $37.22 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $33.61 | $35.37 | $37.22 | +0.39% |
| Week 2 | $33.03 | $35.51 | $38.17 | +0.79% |
| Week 3 | $32.63 | $35.65 | $38.94 | +1.18% |
| Week 4 | $32.31 | $35.79 | $39.63 | +1.58% |
| Week 5 | $32.05 | $35.93 | $40.27 | +1.98% |
| Week 6 | $31.83 | $36.07 | $40.87 | +2.38% |
| Week 7 | $31.63 | $36.21 | $41.45 | +2.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Its portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc. trades in the Healthcare sector under the COLL symbol.
The current price is $35.58 and the market cap is $1.15B.
Its rank is 2447 among listed securities.
Forecasts imply an upside path over time, with the 2026 average price at $35.58 and the 2050 average at $185.24, while the 2050 maximum is $310.47. This indicates a long-run rise in the average price from today toward the mid-to-late decade and beyond.
A major floor 22.2% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
The nearest ceiling, 6.4% above — a clean break opens room to run.
A major ceiling 17.5% above — clearing it would confirm fresh momentum.
Key COLL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COLL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $36.16 | Sell | $35.84 | Sell |
| MA 10 | $36.25 | Sell | $35.84 | Sell |
| MA 20 | $35.30 | Sell | $35.41 | Sell |
| MA 50 | $34.65 | Buy | $35.10 | Buy |
| MA 100 | $35.60 | Sell | $36.14 | Sell |
| MA 200 | $39.21 | Sell | $36.91 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.22 | Neutral |
| Stoch RSI (14) | 17.78 | Buy |
| CCI (20) | -4.69 | Neutral |
| Williams %R (14) | -55.72 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 1.76 | Buy |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 44.28 | Neutral |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | 1.72 | Buy |
| Ultimate (7,14,28) | 46.41 | Neutral |
| Momentum (10) | 0.39 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 35.64 | Sell |
| ADX (14) | 12.83 | Neutral |
| ATR (14) | 0.64 | Info |
The 30-day technical picture is bullish, with sentiment labeled BULLISH and an RSI14 reading of 60.
The trend indicators show a 50-day simple moving average at $34.09 and a 200-day simple moving average at $39.24, with near-term support at $30.48 and resistance at $35.69.
The thirty-day price range spans $31.09 to $40.71, and the stock carries an annualized volatility of 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $30.48 | $35.23 | $45.84 | 0% | Neutral | |
| $31.32 | $38.30 | $49.00 | +9% | Neutral | |
| $32.10 | $40.01 | $52.60 | +14% | Neutral | |
| $36.19 | $45.83 | $61.56 | +30% | Bullish | |
| $38.47 | $49.39 | $67.57 | +40% | Bullish | |
| $44.12 | $57.35 | $79.72 | +63% | Bullish | |
| $50.07 | $65.84 | $92.85 | +87% | Bullish | |
| $49.74 | $66.11 | $94.46 | +88% | Bullish | |
| $52.14 | $70.01 | $101.25 | +99% | Bullish | |
| $53.81 | $72.96 | $106.72 | +107% | Bullish | |
| $79.13 | $112.03 | $171.89 | +218% | Bullish | |
| $133.33 | $202.91 | $334.11 | +476% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $30.48 | $35.23 | $42.38 | +0.00% |
| August 2026 | $31.65 | $37.07 | $44.36 | +5.22% |
| September 2026 | $31.50 | $37.07 | $44.72 | +0.02% |
| October 2026 | $31.05 | $36.70 | $44.57 | -1.01% |
| November 2026 | $31.40 | $37.24 | $45.48 | +1.48% |
| December 2026 | $31.38 | $37.34 | $45.84 | +0.26% |
Click any year to see its month-by-month COLL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect COLL to range from $30.48 to $45.84 through 2026. The $35.23 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The COLL price prediction for 2027 points to an average of $38.30 (low $31.32, high $49.00) — a potential gain of +9% on today's $35.23. Price action looks broadly range-bound.
In 2028, COLL is projected to trade between $32.10 and $52.60, averaging $40.01 — a potential gain of +14% from today's $35.23. That is up +4% on the projected 2027 average. A consolidation phase looks the most probable path here.
Collegium Pharmaceutical, Inc.'s 2029 outlook centres on $45.83, within a $36.19 to $61.56 range. That is up +15% on the projected 2028 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2030, COLL could reach as high as $67.57, with a base case around $49.39 and support toward $38.47 — roughly +40% from $35.23. Buyers look set to stay in control over this stretch.
Expect COLL to range from $44.12 to $79.72 through 2031. The $57.35 average target implies a +63% move from current prices. That is up +16% on the projected 2030 average. Momentum favours further upside here.
The COLL price prediction for 2032 points to an average of $65.84 (low $50.07, high $92.85) — a potential gain of +87% on today's $35.23. Buyers look set to stay in control over this stretch.
In 2033, COLL is projected to trade between $49.74 and $94.46, averaging $66.11 — a potential gain of +88% from today's $35.23. That is up 0% on the projected 2032 average. Momentum favours further upside here.
Collegium Pharmaceutical, Inc.'s 2034 outlook centres on $70.01, within a $52.14 to $101.25 range. That is up +6% on the projected 2033 average. That marks a +99% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, COLL could reach as high as $106.72, with a base case around $72.96 and support toward $53.81 — roughly +107% from $35.23. Momentum favours further upside here.
Expect COLL to range from $79.13 to $171.89 through 2040. The $112.03 average target implies a +218% move from current prices. That is up +54% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The COLL price prediction for 2050 points to an average of $202.91 (low $133.33, high $334.11) — a potential gain of +476% on today's $35.23. Momentum favours further upside here.
Investing $1,000 in COLL today (≈ 28.384899 COLL) could be worth
$5,759.45
+$4,759.45 (+476%) by 2050 · US Dollar
Based on the average projected COLL price of $202.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COLLwould be worth at today's price.
$1,000 invested in COLL on Jul 10, 2025 (≈ 30.30303 COLL) would be worth
$1,067.58
+$67.58 (+6.8%) today · 1.07× · US Dollar
Based on a COLL entry price of $33 vs. today's $35.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $37.03 | $951.39 | -4.9% |
| 1 month ago | $34.8 | $1,012.36 | +1.2% |
| 3 months ago | $35.47 | $993.23 | -0.7% |
| 6 months ago | $48.15 | $731.67 | -26.8% |
| 1 year ago | $33 | $1,067.58 | +6.8% |
| All time (5.0y) ago | $23.44 | $1,502.99 | +50.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COLL forecast.
Our base-case forecast reaches $70.00 around 2034.
Implied market cap at $70.00: $2.27B
The multi-year forecast shows a bullish path with rising averages across the years. The 2026 forecast is min $30.48, avg $35.58, max $45.69 (ROI 0) and sentiment NEUTRAL, while 2029 shows min $34.95, avg $44.55, max $60.39 (ROI 25.2) and sentiment BULLISH. By 2030 the avg is $48.24 with a min of $37.29 and a max of $66.64 (ROI 35.6) and sentiment BULLISH.
The 2040 forecast puts the avg at $107.46 and max at $167.33 (ROI 202) with sentiment BULLISH, and by 2050 the avg reaches $185.24 with a max of $310.47 (ROI 420.6) and sentiment BULLISH.
The year-by-year numbers show a continued rise in the average price through 2029–2050, but these are estimates, not guarantees, and actual results depend on market conditions and other factors.
Tap a question to reveal the answer.
2030 avg $48.24, min $37.29, max $66.64, ROI 35.6, sentiment BULLISH.
The forecast shows bullish sentiment from 2029 onward with rising averages (e.g., 2029 avg $44.55; 2030 avg $48.24; 2040 avg $107.46; 2050 avg $185.24) and growing ROI (e.g., 2029 ROI 25.2; 2030 ROI 35.6; 2050 ROI 420.6). These are estimates, not guarantees.
Yes—the forecast max by 2050 is $310.47, with earlier years showing lower maximums (e.g., 2040 max $167.33). These are projections, not guarantees.
min $30.48, avg $35.58, max $45.69; sentiment NEUTRAL.
Current price $35.58; market cap $1.15B; rank 2447.
Collegium Pharmaceutical, Inc. Community Discussion
0Share your Collegium Pharmaceutical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.